Pharmaceutical composition containing two active ingredients for smoking cessation
CA 2405202 A1 · Owner: Collegium Pharmaceutical, Inc. · Inventors: Junginger, Hans E.; Hirsh, Mark; Midha, Kamal K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises: (a) a therapeutically effective amount of nicotine at, least one active nicotine metabolite a combination of nicotine, and an active nicotine metabolite or an azapirone, or a, pharmaceutically acceptable salt thereof; (b) a transdermal delivery system consisting essentially of a bupropion based in a therapeutically effective amount; and, (c) a packaging material surrounding (a) and (b).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 25, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.